The shares are listed on the Nasdaq Global Select Market

Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by CytomX Therapeutics, Inc. of its common stock for up to an aggregate amount of approximately $58.3 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “CTMX.”

CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company developing novel, conditionally activated, masked biologics designed to be preferentially unmasked and activated in the tumor microenvironment.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Jonathan Bye and Dove Barbanel. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post